Skip to main content Accessibility help

Withdrawal of antipsychotic drugs from adults with intellectual disabilities

  • Claire Stevenson (a1), Lovely Rajan (a2), Gavin Reid (a3), Craig Melville (a4), Robin McGilp (a2) and Sally-Ann Cooper (a5)...


Objectives: There is a view that antipsychotic drugs can be successfully withdrawn from people with intellectual disabilities with resultant health gain. This study critically examines whether antipsychotic drug withdrawal is beneficial.

Methods: 119 adults with intellectual disabilities were included in a programme of antipsychotic drug withdrawal.

Results: The clinical outcomes of this programme are poor. Only 7.6% completely withdrew from antipsychotic drugs, and 48.7% experienced onset/deterioration in problem behaviours or mental ill-health. Significant drug side effects with the introduction of new drugs were experienced by 23.3%. Resultant mean antipsychotic drug doses were higher compared with those at the start of the programme. The cost to the intellectual disabilities psychiatric service (over and above that of routine psychiatric care) was £258,050 (€391,693), and the human cost was considered high. Primary care, social care and family costs were not calculated. The only specific factors found to be associated with poor outcome were increased severity of intellectual disabilities and female gender.

Conclusions: The successful role of antipsychotic drugs in the management of problem behaviours in people who do not have verbal communication skills may relate to the pathoplastic effect of intellectual disabilities on clinical presentation, with problem behaviours being markers of eg. psychosis and anxiety disorders. Our original findings challenge the view that routine withdrawal of antipsychotic drugs is good practice; we reinterpret the existing literature, and recommend caution and vigilance in pharmacotherapy.



Hide All
1.Gualtieri, CT, Schroeder, SR, Hicks, RE, Quade, D. Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 1986; 43: 335340
2.Manchester, D. Neuroleptics, learning disabilities and the community: some history and mystery. BMJ 1993; 307:184187
3.Robertson, J, Emerson, E, Gregory, N, Hatton, C, Kessissiglou, S, Hallam, A. Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellectual Disability Res 2002; 44: 666676
4.Branford, D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities J Intellectual Disability Research 1996; 40: 322329
5.Ahmed, Z, Fraser, W, Kerr, MPet al.Reducing antipsychotic medication in people with a learning disability. Br J Psychiat 2000; 176: 4246
6.Molyneaux, P, Emerson, E, Caine, A. Prescription of psychotropic medication to people with intellectual disabilities in primary health care settings. J App Res Intellectual Disability 2000; 12:4657
7.May, P, London, EB, Zimmerman, T, Thompson, R, Mento, AB, Spreat, S. A study of the clinical outcomes of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 1995; 7:155160.
8.Brylewski, J, Duggan, L. Antipsychotic medication for challenging behaviour in people with learning disability: a systematic review of randomised controlled trials. J Intellectual Disability Res 1999; 43: 360371
9.Department of Health Thioridazine: restricted indications and new warnings on cardiotoxicity, 28/111/12/2000, cem/cmo/2000/18. Department of Health: London, 2000
10.Reilly, JG, Ayis, SA, Ferrier, IN, Jones, SJ, Thomas, SHL. CTC interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:10481052.
11.Hennessy, S, Bilker, Wb, Knauss, JSet al.Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 10701072
12.Reilly, JG, Ayis, A, Ferrier, N, Jones, SJ, Thomas, SHL. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiat 2002; 180: 515522
13.Davies, SJC, Cooke, LB, Moore, AG, Potokar, J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 15191521
14.Arshad, P, Morcos, M, Stidharan, B. Discontinuation of thioridazine: what happened to thioridazine? BMJ 2002; 325: 968
15.Royal College of Psychiatrists DC-LD [Diagnostic Criteria for Psychiatric Disorders for use with Adults with Learning Disabilities/Mental Retardation]. London: Gaskell Press, 2001
16.Netton, A, Rees, T, Harrison, G. Unit Costs of Health and Social Care. PSSRU: University of Kent at Canterbury, 2001
17.Bisset, AF. Discontinuation of thioridazine: risks must be balanced. BMJ 2002; 325, 967968
18.Smith, C, Felce, D, Ahmed, Zet al.Sedation effects on responsiveness: evaluating the reduction of antipsychotic medication in people with intellectual disability using a conditional probability approach. J Intellectual Disability Res 2002; 46: 464471
19.Turner, TH. Schizophrenia and mental handicap: an historical review, with implications for further research. Psych Med 1989; 19: 301314


Related content

Powered by UNSILO

Withdrawal of antipsychotic drugs from adults with intellectual disabilities

  • Claire Stevenson (a1), Lovely Rajan (a2), Gavin Reid (a3), Craig Melville (a4), Robin McGilp (a2) and Sally-Ann Cooper (a5)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.